Paris, June 6, 2013 – Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority):
Total number of outstanding shares
Total number of voting rights
May 31, 2013
Theoretical number of voting
Number of real voting rights: 18,154,432
About BioAlliance Pharma
Dedicated to Specialty Pharma and Orphan products in cancer treatment and in supportive care, with a focus on drug resistance, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and USA; the products’ commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com.
BioAlliance Pharma SA
Judith Gréciet, CEO
Tel.: +33 1 45 58 76 01
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
Tel.: +33 6 64 18 99 59
|ONXEO||Euronext Paris||2.45 (c)||-2.78%||84 357|